The Medicines Discovery Catapult (MDC) has made a significant investment of £1 million into two pioneering UK biotechnology firms focused on developing innovative treatments for chronic autoimmune and neurodegenerative diseases. Each company, Flip Therapeutics and Nascent Therapeutics, will receive £500,000 to expedite the development of their therapeutic platforms. This funding is part of a broader initiative from Innovate UK, which empowers Catapults to invest in promising high-potential companies.
Flip Therapeutics: Reprogramming Immune Responses
Flip Therapeutics is at the forefront of a revolutionary approach aimed at reprogramming T cells within the body. This innovative platform seeks to achieve long-lasting control over immune responses linked to chronic inflammatory and autoimmune conditions, notably alopecia areata and psoriasis.
T cells are crucial in governing immune responses, and disturbances in certain T-cell populations can lead to inflammation and damage to healthy tissues. Flip’s methodology aims to transform disease-driving T cells in vivo into anti-inflammatory cells. This strategy not only seeks to diminish harmful immune activity but also aspires to restore protective immune functions at disease sites.
The funding will enable Flip Therapeutics to validate therapeutic payloads, integrate them with cutting-edge nanoparticle delivery technology, and explore the scalability of its T-cell reprogramming approach. Dr. David Pajerowski, co-founder and CEO, expressed confidence that this infusion of funds and specialist expertise will facilitate focused experiments to validate their innovative methods.
Nascent Therapeutics: Harnessing Mitochondrial Biology
The second recipient of MDC’s investment, Nascent Therapeutics, is a spin-out from the University of East Anglia. This company is dedicated to developing therapies rooted in mitochondrial biology, with a primary focus on Parkinson’s disease and potential applications for other neurodegenerative and age-related disorders.
Mitochondria are essential for energy production in cells and play significant roles in metabolism, inflammation, and oxidative stress. As individuals age, mitochondrial function can decline, contributing to cellular damage and various diseases.
Nascent Therapeutics is pioneering a platform that regulates mitochondrial transfer between cells via the formation of tunnelling nanotubes. These unique structures enable cells to share mitochondria and other vital cellular components. The company is investigating whether enhancing this process could lead to disease-modifying treatments.
Emerging research indicates that mitochondrial transfer may be significant in aging-related conditions, including Parkinson’s and Alzheimer’s diseases. Stuart Wood, co-founder and CEO of Nascent Therapeutics, emphasized that this funding will propel their pipeline development and platform innovation as they strive to create truly novel therapies for Parkinson’s and related aging diseases.
Strategic Support from MDC
The MDC’s investment in Nascent Therapeutics is complemented by collaboration with the venture builder Zinc. This partnership aims to merge capital with translational expertise and strategic direction, ultimately helping both companies mitigate development risks and advance their respective platforms toward clinical applications.
This funding initiative is part of Innovate UK’s broader mission to provide vital capital and specialized support to high-potential businesses across the UK through the Catapult Network.
Conclusion
The investment from MDC marks a promising step forward for both Flip Therapeutics and Nascent Therapeutics in their quest to tackle challenging autoimmune and neurodegenerative diseases. By leveraging innovative approaches and expert guidance, these companies are poised to make significant strides in therapeutic development, potentially transforming patient care in these fields.
- Investment Overview: MDC allocates £1 million to two biotech firms.
- Flip Therapeutics: Focuses on reprogramming T cells for autoimmune diseases.
- Nascent Therapeutics: Explores mitochondrial transfer for neurodegenerative treatments.
- Strategic Partnerships: Collaboration with Zinc enhances support for Nascent.
- Innovate UK: Broader initiative to support high-potential UK biotech firms.
Read more → labnews.co.uk